Prakt. lékáren. 2013; 9(1): 6-8
Everolimus in treatment of Subependymal Giant Cell Astrocytoma
- Ústav farmakologie LF UP a FN Olomouc
Everolimus is a selective immunosuppressant, one of the mTOR inhibitors. It is mostly used in treatment of adult patients to prevent the body
from rejecting a transplanted kidney or heart and in patients with advanced renal cell carcinoma or pancreatic neuroendocrine tumours.
A novel indication is treatment of children with subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis complex who are
not suitable for surgical intervention. Everolimus was approved in this indication in 2011. It is administered orally once daily in dosage of
2.5–7.5 mg. The most common adverse effects include elevated liver enzymes, hypercholesterolemia, increased creatinine levels, stomatitis,
and infections. Everolimus is usually well tolerated. Evidence for effectiveness is based on reduction of SEGA volume in treated children.
Keywords: everolimus, subependymal giant cell astrocytoma, tuberous sclerosis complex, children
Published: March 6, 2013 Show citation
References
- Houghton PJ. Everolimus. Clin Cancer Res. 2010; 16(5): 1368-1372.
Go to original source... 
Go to PubMed... - Turner SG, Peters KB, Vredenburgh JJ, et al. Everolimus tablets for patients with subependymal giant cell astrocytoma. Expert Opin Pharmacother. 2011; 12(14): 2265-2269. Go to original source... Go to PubMed...
- Gurčík L. Tuberózna skleróza z pohľadu neurológa. Neurol. pro Praxi, 2008; 9(3).
- Beaumont TL, Limbrick DD, Smyth MD. Advances in the management of subependymal giant cell astrocytoma. Childs Nerv Syst. 2012; 28(7): 963-968. Go to original source... Go to PubMed...
- Menkes JH, Sarnat HB, Maria BH. Dětská neurologie - II. Díl. Praha: Triton 2011: 1300-1312.
- Goméz MR, Sampson MR, Whittemore VH. Tuberous Sclerosis Complex (Developmental Perspectives in Psychiatry) Third Edition. New York: Oxford University Press 1999: 89.
- Suchý D, Komzáková I, Grundmann M. Základní charakteristiky vybraných imunosupresiv. Klin Farmakol Farm 2004; 18: 90-95.
- Krueger DA, et al. Everolimus for subependymal giantcell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 2010; 363(19): 1801-1811. Go to original source... Go to PubMed...
- Curran MP. Everolimus in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatr Drugs. 2012; 14(1): 51-60. Go to original source... Go to PubMed...
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2012. pii: S0140-6736(12)61134-9.
- Campen CJ, Porter BE. Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update. Curr Treat Options Neurol. 2011; 13(4): 380-385. Go to original source... Go to PubMed...
- https://online.lexi.com/lco/action/doc/retrieve/docid/martindale_f/1354813 14. 1.2013.
- Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 2011.